Gregory Reaman1,2, Dominik Karres3, Franca Ligas3, Giovanni Lesa3, Denise Casey2, Lori Ehrlich2, Koen Norga4,5, Richard Pazdur1,2. 1. Oncology Center of Excellence, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD. 2. Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. 3. Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency, Amsterdam, the Netherlands. 4. Federal Agency for Medicines and Health Products and Paediatric Oncology, Antwerp University Hospital, Edegem, Belgium. 5. European Medicines Agency's Paediatric Committee, European Medicines Agency, Amsterdam, the Netherlands.
Authors: Elly Barry; Darrin Beaupre; Eileen Blasi; Jaimie A Walsh; Scott L Weinrich; Daniel R Arenson; Ira A Jacobs Journal: Paediatr Drugs Date: 2021-06-26 Impact factor: 3.022